The Argentine Society of Rheumatology released 21 evidence-based treatment recommendations for rheumatoid arthritis in 2025, developed by 32 experts who reviewed scientific literature and voted on best practices. According to Gram Research analysis, these recommendations cover medication choices, diet, and strategies for different patient situations, with at least 70% expert agreement on each recommendation. The guidelines address what to do when initial treatments don’t work, when to switch versus add medications, and how to manage patients with lung or blood vessel complications.
The Argentine Society of Rheumatology released updated treatment guidelines for rheumatoid arthritis in 2025, developed by 32 experts who reviewed scientific evidence and voted on 21 recommendations. These guidelines cover everything from diet and medication choices to managing patients with complications. The recommendations address different treatment scenarios, including what to do when initial medications don’t work well enough and when patients can safely reduce their medications. According to Gram Research analysis, these guidelines provide practical tools to help doctors make the best treatment decisions for their individual patients based on current scientific evidence.
Key Statistics
The Argentine Society of Rheumatology’s 2025 update included 21 treatment recommendations for rheumatoid arthritis, developed by 32 experts who reviewed scientific evidence and required at least 70% agreement for each recommendation to be approved.
A systematic review of rheumatoid arthritis treatment evidence by 23 Argentine rheumatology specialists identified specific recommendations for Mediterranean diet, methotrexate delivery methods, and treatment strategies across different clinical scenarios including patients with lung disease or blood vessel inflammation.
The 2025 Argentine rheumatology guidelines addressed 71 specific clinical questions about rheumatoid arthritis treatment, with most recommendations achieving moderate levels of scientific evidence and strong expert consensus.
According to the Argentine Society of Rheumatology’s 2025 update, treatment recommendations cover medication-naive patients, those with inadequate response to initial therapy, and special populations including patients with interstitial lung disease or rheumatoid vasculitis.
The Quick Take
- What they studied: What are the best ways to treat rheumatoid arthritis patients in Argentina, considering local resources and needs?
- Who participated: A team of 32 rheumatology experts from Argentina, including 1 principal investigator, 8 methodologists, and 23 specialist doctors who reviewed medical research and voted on treatment recommendations.
- Key finding: The experts created 21 treatment recommendations with moderate levels of scientific evidence, covering diet, medication types, and strategies for different patient situations. Most recommendations achieved at least 70% agreement among the voting experts.
- What it means for you: If you have rheumatoid arthritis in Argentina, your doctor now has updated, evidence-based guidelines to help choose the best treatment plan for your specific situation. These guidelines consider what works best and what’s practical in your region.
The Research Details
The Argentine Society of Rheumatology assembled a large team of 32 experts to update treatment guidelines for rheumatoid arthritis. The team started by creating 71 specific questions about how to best treat different types of RA patients. They then searched three major medical databases (PubMed, LILACS, and Cochrane Library) plus additional sources to find all relevant scientific studies published on these topics.
The experts evaluated the quality of evidence they found using a standard method called GRADE, which rates how confident we can be in research findings. They then voted anonymously (so no one knew who voted for what) on 21 final recommendations. A recommendation only became official if at least 70% of the experts agreed it was good advice. This voting process happened online to include all team members.
The final recommendations cover practical topics like whether a Mediterranean diet helps, whether to give methotrexate as a shot or pill, and what to do when patients don’t respond well to their first medication. The guidelines also address special situations like patients with lung problems or blood vessel inflammation related to their arthritis.
This approach matters because rheumatoid arthritis treatment isn’t one-size-fits-all. Different patients respond differently to medications, and what works well in one country might not be practical in another due to cost or availability. By having local experts review all the best scientific evidence and create recommendations specifically for Argentina, doctors can make better decisions that fit their patients’ needs and their region’s resources. The use of the GRADE method ensures the recommendations are based on solid science, not just opinion.
This is a high-quality guideline development process because it involved many experts (32 people), used systematic methods to find and evaluate evidence, applied a rigorous quality assessment system (GRADE), and required strong agreement (70%) before recommendations were approved. The anonymous voting reduces bias. However, the authors noted that most recommendations had moderate levels of evidence rather than the strongest possible evidence, meaning doctors should use clinical judgment alongside these guidelines.
What the Results Show
The expert panel developed 21 treatment recommendations covering the full range of rheumatoid arthritis care. These recommendations address initial treatment choices, what to do when patients don’t respond well to their first medication, and how to manage special situations. One key recommendation involves the Mediterranean diet, which the experts found may help RA patients. Another important area covered is whether to give methotrexate (a common RA medication) as an injection under the skin or as a pill by mouth.
The guidelines provide specific strategies for different patient scenarios. For patients who haven’t started strong medications yet, the recommendations guide initial treatment choices. For patients whose symptoms aren’t controlled well enough on their current medication, the guidelines explain whether to try a different medication (swapping) or add another medication (cycling). The recommendations also address when patients in remission (no active disease) can safely reduce or stop their medications.
Special attention was given to patients with complications. The guidelines include specific recommendations for patients who have developed interstitial lung disease (scarring of the lungs) or rheumatoid vasculitis (inflammation of blood vessels) alongside their arthritis. These are serious complications that require careful medication management.
The voting results showed that most recommendations achieved moderate to strong agreement among experts, with at least 70% voting in favor. This indicates good consensus on practical treatment approaches. The fact that experts could reach agreement on complex topics like when to switch versus add medications suggests these recommendations reflect current clinical practice patterns in Argentina. The inclusion of special scenarios (lung disease, blood vessel inflammation) shows the guidelines address real-world complications that doctors encounter.
These 2025 recommendations represent an update to previous Argentine guidelines, incorporating newer research and treatment options that have become available. The systematic approach using GRADE methodology represents a more rigorous evidence-based process than many previous guideline updates. The inclusion of 71 specific clinical questions shows the experts tried to address practical scenarios that doctors face daily, making these guidelines more applicable to real patients than purely theoretical recommendations.
The authors acknowledged that most recommendations had moderate levels of evidence rather than the highest level possible. This means while the recommendations are based on good research, there’s still room for individual clinical judgment. The guidelines are specific to Argentina’s healthcare system and resources, so they may not apply equally well in other countries with different healthcare structures. Additionally, this is Part I of the update, meaning more recommendations may be coming in future parts.
The Bottom Line
Rheumatologists in Argentina should use these 21 recommendations as a practical guide for treating rheumatoid arthritis patients. The recommendations have moderate to strong scientific support (70%+ expert agreement) and cover the most common treatment decisions. Doctors should combine these guidelines with their knowledge of each individual patient’s situation. Patients should discuss these evidence-based options with their rheumatologist to find the best treatment plan for their specific needs.
These guidelines are primarily designed for rheumatologists and doctors treating RA patients in Argentina. Patients with rheumatoid arthritis in Argentina will benefit from doctors using these updated guidelines. The recommendations may also be relevant to healthcare systems in other Spanish-speaking countries with similar resources. Patients outside Argentina should discuss whether these recommendations apply to their situation with their own doctors.
Rheumatoid arthritis treatment typically takes 6-12 weeks to show full effects when starting a new medication. Patients should expect their doctor to monitor their response and adjust treatment if needed. If a medication isn’t working well after 3 months, doctors may switch to a different option following these guidelines. For patients in remission considering medication reduction, the process typically happens gradually over months to ensure disease doesn’t return.
Frequently Asked Questions
What are the new 2025 guidelines for treating rheumatoid arthritis?
The Argentine Society of Rheumatology released 21 evidence-based recommendations covering medication choices, diet, and treatment strategies for different patient situations. The guidelines address initial treatment, what to do when medications don’t work well enough, and how to manage complications like lung disease.
Should I take methotrexate as a pill or injection for rheumatoid arthritis?
The 2025 Argentine guidelines address both subcutaneous (injection) and oral (pill) methotrexate options. Your rheumatologist can help decide which form works best for you based on your individual situation, absorption, and preferences.
Can I reduce my rheumatoid arthritis medications if my symptoms go away?
The 2025 guidelines include recommendations for tapering medications in patients with sustained remission (no active disease). However, this should only be done under close medical supervision with regular monitoring to ensure your disease doesn’t return.
What should I eat if I have rheumatoid arthritis?
The Argentine 2025 guidelines recommend a Mediterranean diet, which emphasizes vegetables, fish, olive oil, and whole grains while limiting red meat. This diet may help reduce inflammation and improve RA symptoms.
What happens if my first rheumatoid arthritis medication doesn’t work?
The 2025 guidelines provide specific recommendations for patients with inadequate response to initial medications. Your doctor may switch to a different medication or add another medication to your treatment plan, depending on your situation.
Want to Apply This Research?
- Track your joint pain and swelling daily using a 0-10 scale for each affected joint, plus note which medications you’re taking and any side effects. This data helps your doctor assess whether your current treatment is working and whether adjustments are needed.
- Work with your doctor to implement the Mediterranean diet recommendation by increasing vegetables, fish, and olive oil while reducing red meat. Log your meals weekly and track any changes in joint symptoms over the following 4-6 weeks.
- Create a monthly check-in where you review your symptom scores, medication adherence, and any new side effects. Share this data with your rheumatologist at appointments to ensure your treatment plan aligns with these evidence-based guidelines and your personal response.
These guidelines are evidence-based recommendations developed by Argentine rheumatology experts and are primarily designed for healthcare providers in Argentina. This information is educational and should not replace consultation with your personal rheumatologist or healthcare provider. Treatment decisions should be individualized based on your specific medical history, current medications, and clinical response. If you have rheumatoid arthritis, discuss these guidelines with your doctor to determine which recommendations apply to your situation. Always follow your healthcare provider’s specific treatment plan and report any new symptoms or medication side effects immediately.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.